Autoimmunity and graves disease

R. S. Bahn

doi:10.1038/clpt.2012.10

Autoimmunity and graves disease

R. S. Bahn

Endocrinology, Diabetes, Metabolism, and Nutrition

Research output: Contribution to journal › Review article › peer-review

33 Scopus citations

Abstract

Current treatment options for Graves hyperthyroidism and the related ophthalmopathy (GO) are not uniformly effective and carry with them potentially serious side effects. As a result, efforts have been focused on the development of novel therapies. Progress has been made, particularly in the production of thyroid-stimulating hormone receptor (TSHR) antagonists, as either monoclonal blocking antibodies or small-molecule ligands. In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions.

Original language	English (US)
Pages (from-to)	577-579
Number of pages	3
Journal	Clinical pharmacology and therapeutics
Volume	91
Issue number	4
DOIs	https://doi.org/10.1038/clpt.2012.10
State	Published - Apr 2012

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1038/clpt.2012.10

Cite this

@article{d39158ad1c15442d8cdfe2e1bf566314,

title = "Autoimmunity and graves disease",

abstract = "Current treatment options for Graves hyperthyroidism and the related ophthalmopathy (GO) are not uniformly effective and carry with them potentially serious side effects. As a result, efforts have been focused on the development of novel therapies. Progress has been made, particularly in the production of thyroid-stimulating hormone receptor (TSHR) antagonists, as either monoclonal blocking antibodies or small-molecule ligands. In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions.",

author = "Bahn, \{R. S.\}",

year = "2012",

month = apr,

doi = "10.1038/clpt.2012.10",

language = "English (US)",

volume = "91",

pages = "577--579",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Autoimmunity and graves disease

AU - Bahn, R. S.

PY - 2012/4

Y1 - 2012/4

N2 - Current treatment options for Graves hyperthyroidism and the related ophthalmopathy (GO) are not uniformly effective and carry with them potentially serious side effects. As a result, efforts have been focused on the development of novel therapies. Progress has been made, particularly in the production of thyroid-stimulating hormone receptor (TSHR) antagonists, as either monoclonal blocking antibodies or small-molecule ligands. In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions.

AB - Current treatment options for Graves hyperthyroidism and the related ophthalmopathy (GO) are not uniformly effective and carry with them potentially serious side effects. As a result, efforts have been focused on the development of novel therapies. Progress has been made, particularly in the production of thyroid-stimulating hormone receptor (TSHR) antagonists, as either monoclonal blocking antibodies or small-molecule ligands. In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions.

UR - https://www.scopus.com/pages/publications/84858759743

UR - https://www.scopus.com/inward/citedby.url?scp=84858759743&partnerID=8YFLogxK

U2 - 10.1038/clpt.2012.10

DO - 10.1038/clpt.2012.10

M3 - Review article

C2 - 22434030

AN - SCOPUS:84858759743

SN - 0009-9236

VL - 91

SP - 577

EP - 579

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 4

ER -

Autoimmunity and graves disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this